PERSONAL INFORMATION

Valentina Di Iorio

Via Sergio Pansini 5, 80131 Napoli, Italy

Mobile 329.7232166

valentina.diiorio@unicampania.it

Medical License: **3768 (Ordine della Provincia di Avellino)**

POSITION

Ophthalmologist

WORK EXPERIENCE

From 2019 to today

University Researcher in Ophthalmology

School of Medicine and Surgery, University of Campania “Luigi Vanvitelli” of Naples, Italy

From 2016 to 2019

Winner of Research Grant entitled "New Strategies for the Diagnosis and Therapy of Retinitis Pigmentosa" funded by the Rome Foundation under the project "Retinitis Pigmentosa: an integrated application of novel strategies towards diagnosis and treatment", Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" SSD: MED / 30, funded by “Fondazione Roma”

2018

National Scientific Qualification, COMPETITION SECTOR 06 / F2 VISUAL APPARATUS DISEASES, II BAND, valid from 10/19/2018 to 10/19/2024 (art. 16, paragraph 1, Law 240/10)

2015

From 2015 member of the Research group: "Inherited retinal disease: from diagnosis to therapy" which has a long experience in the field of clinical research, genetics and experimental therapies as well as advanced diagnostics in relation to hereditary retinal dystrophies.

2014

In 2014 Research grant winner entitled: "Diagnostic, rehabilitative and therapeutic strategies in patients with hereditary retinal degeneration" Research center: Multidisciplinary Department of Medical-Surgical and Dental Specialties; Second University of Napoli. S.S.D .: MED / 30

from 2012 to 2013

Scholarship for the morphological and functional diagnosis of the retina in the research project "A safety and efficacy study in subjects with Leber Congenital Amaurosis (LCA) using Adeno-Associated Viral Vector to deliver the gene for Human RPE65 to the Retinal Pigment Epithelium [AAV2-hRPE65vr-301] treatment and follow-up of 3 Italian patients”- Telethon Foundation, at the Multidisciplinary Department of Medical-Surgical and Dental Specialties, Second University of Naples

from 2009 to 2011

PhD in Nephrological Sciences XXIII cycle - scientific disciplinary sector MED 14, obtained at the Second University of Naples on 11/01/2011, discussing the thesis "Analysis of retinal, renal and audiovestibular alterations in patients with Bardet-Biedl Syndrome: multidisciplinary study" full marks

© European Union, 2002-2013 | http://europass.cedefop.europa.eu

EDUCATION AND TRAINING

8* EQF

From 2003 to 2006

Postgraduate medical training - residency in Ophthalmology

School of Medicine, University of Naples, Naples, Italy

- Specialized clinical and surgical activities in the field of ophthalmology, with a mark of 50/50 with honors discussing the experimental thesis "Genotype-phenotype correlation in Autosomal Dominant Retinitis Pigmentosa".

From 1996 to 2002

Medical Doctor

7* EQF

Degree in Medicine and Surgery obtained at the Second University of Naples, on 15/OCT/2002, full marks and honors, applause of the commission and dignity of press discussing the experimental thesis “Molecular analysis of the gene RP2 in families affected by Retinitis Pigmentosa X-linked ”.

Qualification as Physician-Surgeon at the 1st session of 2003 at the Second University of Naples, Full marks 90/90 - School of Medicine, Second University of Naples, Naples, Italy

Job related training

- ICH Good Clinical Practice E6 (R3) – Telethon – 2025
- ICH Good Clinical Practice E6 (R2) – The Global Health Network – 2025
- BLSD - Croce Rossa Italiana – May 2024
- ACLS American Heart Association – March 2024
- ICH Good Clinical Practice E6 (R2) – The Global Health Network – 2023
- Clinical Research in Italy and The European Regulation, AFI, FADOI, GIDM, SIMeF, 2022
- Pharmacovigilance in clinical research – Telethon - 2021
- BLSD - Croce Rossa Italiana – December 2021
- ACLS - American Heart Association – November 2021
- ICH Good Clinical Practice E6 (R2) – The Global Health Network – 2021
- Introduction to Informed Consent - The Global Health Network – 2021
- Introduction to Collecting and Reporting Adverse Events in Clinical Research - The Global Health Network – 2021
- Introduction to Data Management for Clinical Research Studies - The Global Health Network – 2021
- Essential Good Clinical Practice: GCP, safety reporting, study protocol, data recording, investigational product, trial documentation, retention and archiving – Brookwood International Academy – 2018
- BLSD/ILS/ALS – 2018
- GCP – Telethon – 2017
- CITI Biomedical Refresher Course, Health information privacy and security for the “Center for Cellular and Molecular Therapeutics” - The Children’s Hospital of Philadelphia —2014
- CITI Biomedical Refresher Course for the “Center for Cellular and Molecular Therapeutics” - The Children’s Hospital of Philadelphia – 2011
- CITI (Collaborative Institutional Training Initiative) for the “Center for Cellular and Molecular Therapeutics” – The Children’s Hospital of Philadelphia - GCP in Clinical Research -2008

© European Union, 2002-2013 | http://europass.cedefop.europa.eu

Sub-investigator in the following Clinical trials:

A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults with Stargardt Disease secondary to Mutation in the ABCA4 Gene, AAvantgardeBio, 2024

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects with Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa, AAVantgarde Bio2024

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene, Protocol MGT-RPGR-022, MeiraGTx/Janssen, 2024

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene, Protocol MGT-RPGR-021, 2023

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amaurosis Type 10 (LCA10) due to the c.2991+1655A>G (p.Cys998X) mutation", [PQ-110-005] Pro Qr Therapeutics, 2022

PROQR - Illuminate - Protocol PQ-110-003 -A Double-Masked, Randomized, Controlled, Multiple-Dose Study To Evaluate The Efficacy, Safety, Tolerability And Systemic Exposure Of Qr-110 In Subjects With Leber's Congenital Amaurosis (Lca) Due To C.2991+1655a>G Mutation (P.Cys998x) In The Cep290 Gene. Clinical Ophthalmology, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" 2020

Luxturna Pass Registry trial – Protocol CLTW888A120401 - A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec". Sponsor Novartis; Clinical Ophthalmology, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" 2019

"A phase 3 multicenter, randomized, double-masked, controlled study comparing the efficacy and safety of emixustat hydrochloride with placebo for the treatment of macular atrophy secondary to Stargardt disease", Clinical Ophthalmology, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" 2018

TIGEM3-UshTher-NHS - A Multicentre, Prospective, Longitudinal, Observational Natural History Study to Evaluate Disease Progression in Subjects with Usher Syndrome type 1B (USH1B) Sponsor: Telethon. Clinical Ophthalmology, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" 2018

"A phase 2b randomized, double-masked, controlled TRIAL to establish the safety and Efficacy of Zimura™ (Complement C5 Inhibitor) compared to sham in subjects with Autosomal Recessive Stargardt Disease, Clinical Ophthalmology, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli" 2017

PERSONAL SKILLS

Mother tongue(s): Italian

English, French

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B1	B1	B1	B1	B2

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Author of more than 50 scientific papers on peer reviewed journals

I authorize the processing of my personal data pursuant to Article 13 of Legislative Decree 30 June 2003, no. 196 "Code regarding the protection of personal data and Article 13 of the GDPR 679/16 -" European regulation on the protection of personal data ".
The undersigned, aware of the responsibilities stated in art. 76 of the D.P.R. 445/2000, inherent to the hypothesis of falsification of documents and false declarations, declares that the information above is true.

Dott.ssa Valentina Di Iorio